Enlivex Therapeutics Ltd. (ENLV) Stock Analysis

Why this analysis is different

• A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Enlivex Therapeutics Ltd. (ENLV) Healthcare & Pipeline Overview

Enlivex Therapeutics Ltd., a clinical-stage biotechnology company, specializes in macrophage reprogramming immunotherapy. Their primary asset, Allocetra, is undergoing Phase II clinical trials for sepsis-related organ dysfunction and preclinical trials for solid tumors, positioning them in the innovative yet high-risk segment of cell-based therapies.

What Is the Investment Thesis for ENLV?

Enlivex Therapeutics presents a high-risk, high-reward investment opportunity centered on its novel macrophage reprogramming technology. The primary value driver is Allocetra, currently in Phase II trials for sepsis-related organ dysfunction. Positive trial results could lead to significant stock appreciation. The company's market capitalization of $25.3M reflects the early stage of development and associated risks. Key catalysts include the progression of Allocetra through clinical trials and potential partnerships with larger pharmaceutical companies. However, risks include clinical trial failures, regulatory hurdles, and the need for additional funding. Investors should closely monitor clinical trial data and the company's cash runway.

Based on FMP financials and quantitative analysis

ENLV Key Highlights

Allocetra is in Phase II clinical trials for the treatment of organ dysfunction and failure associated with sepsis.

• Preclinical trials are underway to assess Allocetra's efficacy in treating solid tumors.
• Enlivex Therapeutics Ltd. operates as a clinical-stage company, indicating reliance on successful clinical trial outcomes.
• The company's market capitalization is $0.02 billion.
• Enlivex is headquartered in Nes Ziona, Israel, with a team of 71 employees.

Who Are ENLV's Competitors?

ENLV is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are ENLV's Key Strengths?

Novel macrophage reprogramming technology.

• Potential to address unmet needs in sepsis treatment.
• Ongoing clinical trials for Allocetra.
• Experienced management team.

What Are ENLV's Weaknesses?

Clinical-stage company with no approved products.

• Reliance on successful clinical trial outcomes.
• Limited financial resources.
• High risk of clinical trial failure.

What Could Drive ENLV Stock Higher?

ENLV catalyst: Interim data readout from the Phase II clinical trial of Allocetra for sepsis-related organ dysfunction (2026).

• Initiation of Phase III clinical trials for Allocetra, contingent on positive Phase II results (2027).
• Progression of preclinical trials for Allocetra in solid tumors.
• Potential partnership announcements with larger pharmaceutical companies.

What Are the Key Risks for ENLV?

Financial-distress signal — its Altman Z-Score of 1.58 sits in the distress zone (elevated bankruptcy risk).

• Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
• Failure to achieve positive results in clinical trials.
• Regulatory delays or rejection of Allocetra.
• Competition from other companies developing therapies for sepsis and cancer.
• Dependence on securing additional funding to support research and development.
• Intellectual property challenges or patent infringement.

What Are the Growth Opportunities for ENLV?

• Expansion into New Therapeutic Areas: Enlivex has the opportunity to expand the application of Allocetra beyond sepsis and solid tumors into other inflammatory and immune-related diseases. This could significantly broaden the market potential for the therapy. The market size for autoimmune disease treatments is projected to reach $150 billion by 2028, presenting a substantial growth opportunity. Timeline: 3-5 years, contingent on successful clinical trials.
• Strategic Partnerships: Collaborating with larger pharmaceutical companies for development and commercialization could accelerate the adoption of Allocetra and provide access to broader resources and expertise. Strategic partnerships can provide financial support and accelerate the regulatory approval process. Timeline: 1-2 years, dependent on partnership negotiations.
• Geographic Expansion: Expanding clinical trials and eventual commercialization efforts into new geographic markets, such as the United States and Europe, could significantly increase revenue potential. The global sepsis therapeutics market is expected to reach $1.2 billion by 2027. Timeline: 2-4 years, contingent on regulatory approvals and market access.
• Advancements in Manufacturing Process: Improving the efficiency and scalability of the Allocetra manufacturing process could reduce production costs and increase profit margins. Streamlining manufacturing can also ensure a consistent supply of the therapy for clinical trials and commercialization. Timeline: Ongoing, continuous improvement efforts.
• Positive Clinical Trial Data: Successful completion of Phase II clinical trials for sepsis and advancement into Phase III trials would be a major catalyst for growth. Positive data would validate the efficacy of Allocetra and increase investor confidence. Timeline: 1-2 years, dependent on trial progress and data analysis.

What Threats Does ENLV Face?

• Competition from established pharmaceutical companies.
• Regulatory hurdles and delays.
• Unexpected adverse events in clinical trials.
• Difficulty in securing additional funding.

What Are ENLV's Competitive Advantages?

• Proprietary macrophage reprogramming technology.
• Patent protection for Allocetra and related methods.
• First-mover advantage in a niche segment of the immunotherapy market.
• Clinical data demonstrating the potential efficacy of Allocetra.

What Does ENLV Do?

Enlivex Therapeutics Ltd., founded in 2005 and headquartered in Nes Ziona, Israel, is a clinical-stage biotechnology company focused on developing macrophage reprogramming immunotherapies. The company’s lead product candidate, Allocetra, is a cell-based therapy designed to treat organ dysfunction and failure associated with sepsis. Allocetra is currently in Phase II clinical trials for this indication. Additionally, Enlivex is exploring Allocetra's potential in treating solid tumors through preclinical trials. The company's approach centers on modulating the immune system to resolve life-threatening conditions. Enlivex aims to address critical unmet needs in severe inflammatory and immune-related diseases. Their research and development efforts are concentrated on harnessing the power of macrophages to restore immune balance and prevent organ damage. As a clinical-stage company, Enlivex is heavily reliant on successful clinical trial outcomes and regulatory approvals to advance Allocetra to market. The company operates primarily in Israel, with plans to expand its clinical trial sites globally as development progresses. Enlivex faces competition from larger pharmaceutical companies and other biotechnology firms developing therapies for sepsis and cancer.

What Products and Services Does ENLV Offer?

• Develop macrophage reprogramming immunotherapies.
• Focus on cell-based therapies for severe inflammatory and immune-related diseases.
• Conduct clinical trials to evaluate the safety and efficacy of Allocetra.
• Target organ dysfunction and failure associated with sepsis.
• Explore the potential of Allocetra in treating solid tumors.
• Research and develop novel approaches to modulate the immune system.

How Does ENLV Make Money?

• Develop and patent novel immunotherapies.
• Conduct clinical trials to demonstrate safety and efficacy.
• Seek regulatory approval for commercialization.
• Potentially partner with larger pharmaceutical companies for manufacturing and distribution.
• Generate revenue through product sales or licensing agreements.

What Industry Does ENLV Operate In?

Enlivex Therapeutics operates within the biotechnology industry, which is characterized by high research and development costs, lengthy regulatory approval processes, and significant competition. The market for sepsis treatments is substantial, driven by the high mortality rates and limited effective therapies. The company's focus on macrophage reprogramming immunotherapy places it within a niche segment of the broader immunotherapy market, which is experiencing rapid growth due to advancements in understanding the immune system's role in disease. Competition includes established pharmaceutical companies and other biotechnology firms developing novel therapies for sepsis and cancer.

Who Are ENLV's Key Customers?

• Hospitals and medical centers treating patients with sepsis.
• Oncologists and cancer treatment centers.
• Patients suffering from severe inflammatory and immune-related diseases.
• Pharmaceutical companies seeking to license or acquire novel therapies.

How Enlivex Therapeutics Ltd. Is Valued

Enlivex Therapeutics Ltd. carries a market capitalization of $25.3M, placing it in the micro-cap category. Relative to its peer group, ENLV's quantitative score of 46/100 is below the peer average of 76/100.

Company Profile

Enlivex Therapeutics Ltd. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Ness Ziona, IL. The company is led by CEO Oren Hershkovitz. ENLV has traded publicly since 2014.

Return on equity for Enlivex Therapeutics Ltd. stands at 248.1%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 53.1%, showing how much profit it generates from its asset base. ENLV trades at a trailing price-to-earnings ratio of 0.03, below the Healthcare sector average of ~23x. Its free cash flow yield is -83.0%, a gauge of the cash the business throws off relative to its market value.

Enlivex Therapeutics Ltd.'s Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of 1.58 places it in the distress zone, a signal of elevated financial risk.

Enlivex Therapeutics Ltd. has beaten Wall Street's EPS estimate in 6 of its last 8 reported quarters — a consistent record of delivering on expectations. Reported results have landed about 3926.3% above estimates on average.

Wall Street analysts project Enlivex Therapeutics Ltd. revenue of about $0 for fiscal 2026, with EPS near $-1.20.

ENLV Financials

ENLV Latest News

ENLV Analyst Consensus

ENLV MoonshotScore

Enlivex Therapeutics Ltd. Healthcare Stock: Key Questions Answered

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources